search
Back to results

Comparison of the Effectiveness of Bowel Preparations Before Colonoscopy

Primary Purpose

Colorectal Neoplasms

Status
Unknown status
Phase
Not Applicable
Locations
Czechia
Study Type
Interventional
Intervention
colonoscopy
colonoscopy
colonoscopy
colonoscopy
Sponsored by
Military University Hospital, Prague
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional diagnostic trial for Colorectal Neoplasms focused on measuring colorectal neoplasia, colonoscopy, quality of bowel cleansing, bowel preparation

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

• Individuls ≥ 18 years old undergoing colonoscopy for all indications except exclusion criteria

Exclusion Criteria:

  • Active idiopathic bowel disease
  • Chronic renal insufficiency
  • Serious internal comorbidity
  • Planned therapeutic colonoscopy
  • No informed consent signed (with the study and/or with the colonoscopy)

Sites / Locations

  • Military University HospitalRecruiting

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm 4

Arm Type

Experimental

Experimental

Experimental

Experimental

Arm Label

PEG group

SBS group

PEG 2L + ascorbic acid group

PICO group

Arm Description

100 patients undergoing colonoscopy.

100 patients undergoing colonoscopy

100 patients undergoing colonoscopy.

100 patients undergoing colonoscopy.

Outcomes

Primary Outcome Measures

Quality of bowel cleansing according to Boston Bowel Preparation Scale (BBPS)
0-Unprepared colon segment with mucosa not seen due to solid stool that cannot be cleared 1-Portion of mucosa of the colon segment seen, but other areas of the segment are not well seen due to staining, residual stool, and/or opaque liquid 2-Minor amount of residual staining, small fragments of stool and/or opaque liquid, but mucosa colon segment is seen well 3-Entire mucosa of colon segment seen well, with no residual staining, small fragment of stool or opaque liquid

Secondary Outcome Measures

Detection of colorectal neoplasia
In each colonoscopy the number of colorectal neoplasia will be rated. Colorectal neoplasia is defined by these two types of lession: advanced adenoma - 1cm size or greater or with villous component or with high grade dysplasia carcinoma

Full Information

First Posted
July 18, 2017
Last Updated
January 31, 2018
Sponsor
Military University Hospital, Prague
Collaborators
Masaryk University
search

1. Study Identification

Unique Protocol Identification Number
NCT03242369
Brief Title
Comparison of the Effectiveness of Bowel Preparations Before Colonoscopy
Official Title
Comparison of the Effectiveness of Bowel Preparations in Bowel Cleansing Before Colonoscopy - Prospective, Randomized Study
Study Type
Interventional

2. Study Status

Record Verification Date
January 2018
Overall Recruitment Status
Unknown status
Study Start Date
September 1, 2017 (Actual)
Primary Completion Date
December 31, 2018 (Anticipated)
Study Completion Date
March 31, 2019 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Military University Hospital, Prague
Collaborators
Masaryk University

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
Polyethylene glycol is the gold standard of bowel preparation for colonoscopy. The most important disadvantage is high volume of this preparation. Sulphate based solution (SBS), low volume PEG + ascorbic acid and solution of magnesium citric acid and sodium picosulfate could be suitable substitution of polyethylene glycol.
Detailed Description
This study will be unicenter, randomized and single blind. It focuses on studying the effectiveness of four preparations for bowel cleansing before colonoscopy. Polyethylenglycol (PEG) will be compared as a gold standard of bowel cleansing with low volume preparations: Sulfate-based solution (SBS), low volume PEG + ascorbic acid and solution of magnesium citric-acid and sodium picosulfate. The effectiveness will be rated according to a quality of bowel preparation (Boston Bowel Preparation Scale) and detection of a colorectal neoplasia. The aim of this project is to compare the effectiveness of each four preparations. Primary endpoint: To compare a quality of bowel preparation. Secondary endpoint: To compare a detection of colorectal neoplasia in those preparations. Main hypothesis: PEG as a gold standard of bowel cleansing preparation is not worse than the other compared preparations. Secondary hypothesis: PEG is not worse in detection of colorectal neoplasia than the other compared preparations. Methods: There will be 400 patients included in the project with all indications for colonoscopy (age ≥ 18 years, no upper age limit) except the exclusion criteria. The patients will be offered to participate in the study at the Endoscopy unit when arranging the examination. In case of agreement they will sign informed consent and they will be educated about the correct process of bowel preparation. They also get all the instructions in printed version and questionnaire of preparation tolerability. The advantages for the patients in study will be earlier date of colonoscopy. On the day of colonoscopy, the patients will submit the questionnaire and undergo standard colonoscopy examination. The quality of a bowel cleansing will be evaluated by the experienced endoscopists who will be blinded about a type of bowel preparation. The effectiveness will be assessed by the degree of bowel cleansing (Boston Bowel Preparation Scale) and ADR, aADR and number of cancers diagnosed. The GE unit staff will record all results in the on-line study database. Results will be statistically evaluated in Institute of Biostatistics and Analyses, Masaryk University, IBA MU).

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Colorectal Neoplasms
Keywords
colorectal neoplasia, colonoscopy, quality of bowel cleansing, bowel preparation

7. Study Design

Primary Purpose
Diagnostic
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
400 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
PEG group
Arm Type
Experimental
Arm Description
100 patients undergoing colonoscopy.
Arm Title
SBS group
Arm Type
Experimental
Arm Description
100 patients undergoing colonoscopy
Arm Title
PEG 2L + ascorbic acid group
Arm Type
Experimental
Arm Description
100 patients undergoing colonoscopy.
Arm Title
PICO group
Arm Type
Experimental
Arm Description
100 patients undergoing colonoscopy.
Intervention Type
Procedure
Intervention Name(s)
colonoscopy
Intervention Description
100 patients undergoing colonoscopy will be prepared with split dose (2+2l) PEG. 2 liters will be drunk during 2 hours in the evening the day before colonoscopy, the second 2l during 2 hours in the day of colonoscopy finishing the dose 4- 6 hours before colonoscopy.
Intervention Type
Procedure
Intervention Name(s)
colonoscopy
Intervention Description
100 patients undergoing colonoscopy will by prepared with split dose of SS. The first bottle of SS with water (total volume 0,5l) will be drunk in the evening the day before colonoscopy during 1 hour, than another 1liter of clear fluid will be drunk. The same procedure will be repeated with the second bottle of SS finishing at least 3 hours before colonoscop
Intervention Type
Procedure
Intervention Name(s)
colonoscopy
Intervention Description
100 patients undergoing colonoscopy will be prepared with split dose of PEG (1+1L) with ascorbic acid. The first 1l of solution will be drunk in the evening the day before colonoscopy, the second 1l of solution in the day of colonoscopy finishing 4-6 hours before the examination. Another 1l of clear fluid should be drunk during the cleansing process.
Intervention Type
Procedure
Intervention Name(s)
colonoscopy
Intervention Description
100 patients undergoing colonoscopy will be prepared with split dose (150ml +150ml) of solution of magnesium acid and sodium picosulfate. The first dose will be drunk in the evening the day before colonoscopy, then at least 1l of another clear fluid will be drunk within a few hours, the second dose will be drunk in the day of examination finishing 4-6hours before colonoscopy and then another at least 750ml clear fluid.
Primary Outcome Measure Information:
Title
Quality of bowel cleansing according to Boston Bowel Preparation Scale (BBPS)
Description
0-Unprepared colon segment with mucosa not seen due to solid stool that cannot be cleared 1-Portion of mucosa of the colon segment seen, but other areas of the segment are not well seen due to staining, residual stool, and/or opaque liquid 2-Minor amount of residual staining, small fragments of stool and/or opaque liquid, but mucosa colon segment is seen well 3-Entire mucosa of colon segment seen well, with no residual staining, small fragment of stool or opaque liquid
Time Frame
1 day
Secondary Outcome Measure Information:
Title
Detection of colorectal neoplasia
Description
In each colonoscopy the number of colorectal neoplasia will be rated. Colorectal neoplasia is defined by these two types of lession: advanced adenoma - 1cm size or greater or with villous component or with high grade dysplasia carcinoma
Time Frame
1 day

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: • Individuls ≥ 18 years old undergoing colonoscopy for all indications except exclusion criteria Exclusion Criteria: Active idiopathic bowel disease Chronic renal insufficiency Serious internal comorbidity Planned therapeutic colonoscopy No informed consent signed (with the study and/or with the colonoscopy)
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Stepan Suchanek, MD., PhD.
Phone
973208367
Ext
00420
Email
stepan.suchanek@uvn.cz
First Name & Middle Initial & Last Name or Official Title & Degree
Klara Kmochova, MD.,
Phone
973203076
Ext
00420
Email
klara.kmochova@uvn.cz
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Stepan Suchanek, MD., PhD.
Organizational Affiliation
Military Univesity Hosital Prague
Official's Role
Study Director
Facility Information:
Facility Name
Military University Hospital
City
Prague
ZIP/Postal Code
16902
Country
Czechia
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Stepan Suchanek, MD., Ph.D.

12. IPD Sharing Statement

Learn more about this trial

Comparison of the Effectiveness of Bowel Preparations Before Colonoscopy

We'll reach out to this number within 24 hrs